派格生物医药-B(02565)拟全球发售1928.35万股 引入益泽康瑞作为基石投资者

Core Viewpoint - The company, Paige Biopharma-B (02565), is set to launch an IPO from May 19 to May 22, 2025, aiming to raise approximately HKD 231.8 million through the global offering of 19.2835 million shares at a price of HKD 15.60 per share, with a focus on innovative therapies for chronic diseases, particularly in the metabolic disorder sector [1][3]. Company Overview - Established in 2008, the company specializes in the research and development of innovative therapies for chronic diseases, focusing on peptide and small molecule drugs, particularly in the area of metabolic disorders [1]. - The company has developed a core product and five other candidate products targeting common chronic and metabolic diseases such as Type 2 Diabetes Mellitus (T2DM), obesity, Non-Alcoholic Steatohepatitis (NASH), Opioid-Induced Constipation (OIC), and Congenital Hyperinsulinism [1]. Product Details - The core product, PB-119, is a long-acting GLP-1 receptor agonist nearing commercialization, primarily used for the first-line treatment of T2DM and obesity, showing benefits in blood sugar control and cardiovascular health [2]. - PB-119's New Drug Application (NDA) for T2DM treatment in China was accepted by the National Medical Products Administration in September 2023, marking a significant milestone towards commercialization [2]. Fund Allocation - Approximately 50.2% of the net proceeds from the IPO will be allocated to the commercialization and indication expansion of PB-119, while 34.5% will be used for the further development of the main product PB-718 [3]. - Other allocations include 5.3% for ongoing and planned R&D of other pipeline candidates, 1.0% for business development and enhancing overseas operations, and 9.0% for working capital and general corporate purposes [3]. Cornerstone Investor - The company has signed a cornerstone investment agreement with Yizhe Kangrui Pharmaceutical (Hong Kong) Co., Ltd., which will subscribe to approximately 12.692 million shares, representing about 65.82% of the global offering and approximately 3.29% of the total issued share capital post-offering [3][4]. - Yizhe Kangrui is wholly owned by Hangzhou Gongshu National Investment Innovation Development Co., Ltd., which has extensive investment experience in the life sciences sector [4].